Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.

INTRODUCTION

Hematological and oncological diseases collectively affect a substantial number of patients. Pulmonary hypertension (PH) is recognized as a potential rare complication associated with these conditions, manifesting in various forms of PH and presenting with a range of symptoms. This review aimed to summarize recent research findings and enhance the understanding of the complex interactions between PH and hemato-oncological diseases.

METHODS

This narrative review synthesizes recent research findings to explore the interplay between PH and hematological or oncological diseases. A comprehensive search of relevant literature was conducted using PubMed.

RESULTS

The complexity of PH in this context arises from its multifactorial etiology, which can include direct effects of malignancies, treatment-related effects, and the impact of disease progression. The variability in how PH presents and progresses in patients with hematological diseases and neoplasms complicates its diagnosis and management. Accurate identification of PH alongside the underlying condition is crucial for enabling optimal treatment and improving overall survival. A multidisciplinary approach is essential to address these challenges effectively.

CONCLUSION

PH in hematologic and oncologic diseases can result from multiple causes. Following a systematic workup, a multidisciplinary approach to management is crucial to ensure optimal treatment and improve survival.